Medicare drug plans may limit coverage of quadruple drug therapy for heart failure with reduced ejection fraction (HFrEF) through cost sharing, resulting in out-of-pocket (OOP) costs considerably higher than generic regimens and potentially unaffordable for many Medicare patients, according to a study published June 20 in the Journal of the American College of Cardiology. Kamil F. Faridi, MD, et…
Debabrata Mukherjee, MD, FACC
The ACC is leading the transformation of care by advocating for a quality driven health care system, provider stability, population health and the future of…
The U.S. Food and Drug Administration (FDA) announced on April 15 that Abbott/Thoratec Corp. is recalling the Heartmate II and Heartmate 3 Left Ventricular Assist…
∗Address for correspondence: Ms Cathleen Biga, American Coll ege of Cardiology, 2400 N Street, NW, Washington, DC 20037, USA. E-mail: E-mail Address: [email protected] As…
Join ACC President B. Hadley Wilson, MD, FACC (@HadleyWilsonMD), for his new Heart-to-Heart presidential chat series focused on ACC members and their inspiring work to…
Elizabeth A. Jackson, MD, FACC
Debabrata Mukherjee, MD, FACC
United by our shared commitment of transforming cardiovascular care, the American College of Cardiology (ACC) and the Egyptian Society of Cardiology invite you to join…
